The etiology, clinical presentation, and management of pseudomyxoma peritonei
Brendan J Moran1, Thomas D Cecil
1Pseudomyxoma Peritonei Centre, North Hampshire Hospital, Aldermaston Road, Basingstoke, Hampshire, RG24 9NA, United Kingdom. Brendan.Moran@nhht.nhs.uk
Abstract:
PMP is a rare condition, which, although of "borderline malignancy," is invariably fatal. Difficulties exist with the definition of PMP. It has been broadly applied to include a heterogenous group of pathologic lesions that present clinically with "jelly belly" due to mucinous ascites. The relatively few reports in the literature commonly use different pathologic definitions, and there is no consensus on the point of separation between PMP and carcinomatosis secondary to a mucinous adenocarcinoma. Sugarbaker has suggested "the term pseudomyxoma peritonei syndrome be strictly applied to a pathologically and prognostically homogenous group of cases characterized by histologically benign peritoneal tumors that are frequently associated with an appendiceal mucinous adenoma." This definition excludes all cases with mucinous adenocarcinoma. The optimal treatment is undoubtedly complete tumor excision, by complex surgical peritonectomy procedures, taking on average 10 hours. Surgery is usually combined with intraperitoneal, and now intraoperative heated chemotherapy. These techniques have a high morbidity and mortality. The rarity of the condition, together with the risks associated with definitive treatment, suggests that such treatment ought to be centralized in a few centers, covering a large population. The search continues for safer, less aggressive treatments, but is hampered by a lack of hard evidence and the absence of experimental animal or human models to evaluate emerging strategies.
Insights
Pseudomyxoma peritonei (PMP) is a rare, fatal condition often presenting as "jelly belly." Optimal treatment involves extensive surgery and chemotherapy, necessitating centralized care due to high risks.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Pseudomyxoma peritonei (PMP) is a rare malignancy with unclear definitions, often presenting with mucinous ascites ('jelly belly').
- Existing literature lacks a consensus on pathological definitions, creating challenges in differentiating PMP from secondary mucinous adenocarcinoma.
- Sugarbaker's proposed definition emphasizes histologically benign peritoneal tumors, often linked to appendiceal adenoma, excluding adenocarcinoma.
Purpose of the Study:
- To clarify the definition and diagnostic challenges of Pseudomyxoma Peritonei (PMP).
- To discuss the optimal, albeit high-risk, treatment strategies for PMP.
- To highlight the need for centralized treatment centers and further research into safer therapies.
Main Methods:
- Literature review and synthesis of existing pathological and clinical data on PMP.
- Analysis of proposed definitions, including Sugarbaker's criteria for a homogenous PMP group.
- Discussion of current treatment modalities, including surgical peritonectomy and heated intraperitoneal chemotherapy.
Main Results:
- PMP is characterized by mucinous ascites and presents diagnostic difficulties due to heterogeneous pathological classifications.
- Complete tumor excision via extensive peritonectomy, often combined with heated chemotherapy, is considered optimal but carries significant morbidity and mortality.
- The rarity and complexity of PMP treatment support centralization of care in specialized high-volume centers.
Conclusions:
- Standardized pathological definitions are crucial for accurate PMP diagnosis and research.
- Centralized management in expert centers is recommended for PMP patients due to treatment complexity and risks.
- Further research is needed to develop safer, less aggressive treatments, requiring robust evidence and experimental models.
More Related Videos
Related Concept Videos
01:28Esophageal Perforation-II: Clinical Manifestations and Management
Clinical Manifestations:
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:22Appendicitis-I: Introduction
Etiology: Appendicitis can arise from various causes, primarily rooted in the obstruction of the appendix lumen. Factors contributing to this obstruction include fecal accumulation, lymphoid hyperplasia and, in...
01:19Pericarditis II: Clinical Features and Diagnostic Tests
01:14Atypical Pneumonia